No Data
No Data
MetaVia to Present at the Emerging Growth Conference in December
NeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthy
Express News | NeuroBo Pharmaceuticals Inc: Common Stock Will Begin Trading on Nasdaq Under "Mtva," Which Is Expected to Be Operative as of November 29
Express News | NeuroBo Pharmaceuticals Inc: Strategic Realignment Ahead of Important Clinical Milestones With Name Change to Metavia
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones With Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation